Survival was noted from time of histological confirmation of pancreatic adenocarcinoma (80%) or of unequivocal radiological or operative findings in those for whom histological confirmation was not obtained. Approval for the study was obtained from the Lothian Ethical Committee.
IL-1β genotyping
DNA was extracted from 1 ml samples of EDTA anticoagulated blood using a Puregene DNA isolation kit based on a simple salting out technique (Miller et al, 1988 ) (Gentra systems, North Carolina, USA). The polymerase chain reaction (PCR) was used to amplify a 699 bp fragment of the IL-1β genomic sequence using primers upstream 5′ TGT TCT TAG CCA CCC CAC TC 3′ and downstream 5′ ATC GCT CCA GCA CTC TTG TT 3′ (Genosys, Pampisford, UK) designed on the basis of the published sequence (Clark et al, 1986 ) using the Primer 3 program (Rozen and Skaletsky, 1996) . The following PCR protocol was used -3 cycles of 97°C for 1.5 minutes, 54°C for 1.5 minutes, 74°C for 1 minute; 32 cycles of 97°C for 0.5 minutes, 54°C for 0.5 minutes, 74°C for 1.5 minutes; and 72°C for 10 minutes using reagents supplied by Promega (Southampton, UK) on a Hybaid Omn-E thermal cycler (Teddington, UK). The PCR product was digested directly with 0.5 µ of TaqI restriction enzyme (Appligene, Chester-le-Street, UK) at 65°C for 4 hours. Restriction enzyme products were analysed on 1% NuSieve agarose (FMC bioproducts, Rockland, Maine, USA) or 6% polyacrylamide gels (Biorad, Hemel Hempstead, UK). The cleaved product produced bands at 524 and 175 bp representing allele 1 while the uncleaved 699 bp product represented allele 2 (Figure 1 ).
Cytokine production
Serum IL-1β levels were measured by ELISA (Quantikine High Sensitivity, R & D System, Abingdon, UK). Limit of detection was 0.2 pg ml -1 . PBMCs were separated from 20 ml of heparin anticoagulated blood on a hypaque gradient (Histopaque 1077, Sigma, Poole, UK) by centrifuging at 1500 rpm for 30 minutes. Cells from the interface were removed and washed three times in cell culture medium (Roswell Park Memorial Institute medium 1640, Life Technologies, Paisley, UK) with penicillin, streptomycin and glutamine (2 mmol l -1 ) (Sigma) added. Cells were resuspended, counted and cultured in 96-well, flat-bottomed tissue culture plates (Corning Coster, High Wycombe, UK) at a concentration of 2 × 10 5 per well in 200 µl cell culture medium with 10% fetal calf serum in the presence of 10 µg ml -1 E. coli lipopolysaccharide (Sigma). Supernatants from PBMC cultures were removed at 24 hours and stored at -70°C for subsequent analysis. IL-1β content of supernatants was measured by ELISA (Quantikine, R & D Systems, Abingdon, UK). Limit of detection was 4 pg ml -1 . Serum CRP levels were measured by an automated immunoturbidometric method (Abbott Laboratories, Maidenhead, UK). Limit of detection was 10 mg l -1 . There was no significant difference in the distribution of genotypes between pancreatic cancer patients and healthy controls. IL-1β was only detectable in serum from two patients (without infection or jaundice). One patient of genotype 2/2 had a serum level of 7.24 pg ml -1 while a patient of 1/2 genotype had a level of 1.16 pg ml -1 . Both patients had substantially elevated serum CRP levels at 151 and 53 mg l -1 respectively. IL-1β production by PBMCs from cancer patients (without evidence of infection or jaundice, approximately 1 month after diagnosis, surgery or endobiliary stenting) by IL-1β genotype is presented in Figure 2 . PBMC IL-1β production by those with a 2/2 genotype (median 9.7 ng ml -1 (range 7.9-11.5)) was significantly higher than those with 1/2 (2.2 (interquartile range 1.5-2.7), P = 0.046) or 1/1 (1.9 (1.4-2.6), P = 0.027) genotype. There was no significant difference between PBMC IL-1β production between 1/2 and 1/1 genotype (P = 0.72). There was no significant relationship between PBMC IL-1β production and CRP level (r = 0.28, P = 0.21).
Statistical analysis
Serum Figure 3 . CRP levels from those with the 2/2 (28 mg l -1 (20-130)) or 1/2 genotype (31 mg l -1 (13-72)) were significantly higher than those with the 1/1 genotype (0 mg l -1 (0-10)) (P = 0.015 and 0.0042, respectively). There was no significant difference between CRP levels from those with 2/2 and 1/2 genotypes (P = 0.42).
Survival of patients by IL-1β genotype is presented in Figure 4 . Those with 2/2 genotype (88 days (69-108)) had significantly shorter survival than those with 1/2 (173 days (107-269)) or 1/1 (243 days (126-333)) genotype (P = 0.012 and 0.0001 respectively). The difference between survival of those with 1/1 and 1/2 genotype is not quite significant (P = 0.10). All 4 censored individuals possess the 1/1 genotype. Those possessing allele 2 had significantly shorter survival (148 days (85-245)) than those who did not (243 days (126-333)) (P = 0.043) ( Figure 5 ).
Disease stage was not a significant predictor of survival in this group of patients (P = 0.65). When survival by IL-1β genotype was split by disease stage genotype remained a significant predictor of survival in those with stage II and IV disease where sufficient numbers were available for analysis (P = 0.025 and P = 0.028, respectively).
For predicting survival at 6 months the possession of allele 2 has a sensitivity of 48%, a specificity of 81%, a positive predictive value of 65%, a negative predictive value of 67% and an accuracy of 67%.
DISCUSSION
In this study of patients with advanced pancreatic cancer we have shown that IL-1β genotype appears to be important in determining IL-1β production, serum CRP level and survival from diagnosis.
There was no difference in the distribution of genotypes between normal subjects and cancer patients. The distribution found in normal subjects is very similar to that described in other European populations (Pociot et al, 1992; Bioque et al, 1995; Heresbach et al, 1997) . There was a trend towards fewer cancer patients possessing allele 2. If possession of allele 2 shortens survival we may have missed some patients who died before assessment, thus our estimate of the importance of allele 2 may be a conservative one.
It is rare to detect IL-1 in the serum of cancer patients, thus measures of production are more important for gauging in vivo levels (Moldawer and Copeland, 1997) . Only one group has previously studied the relationship between this IL-1β polymorphism and production of IL-1β by leukocytes (Pociot et al, 1992) . Examining a group of 45 healthy individuals they were able to show a stepwise increase in IL-1β production from 1/1 to 1/2 to 2/2 genotype. While numbers in the present study were insufficient to confirm this relationship, differences between the 2/2 genotype and the other groups were significant and there was a marked trend in agreement with this previous study (P = 0.072 -Kruskal-Wallis test).
The relationship between IL-1β genotype and the acute phase protein response has not previously been examined. It is known that the administration of IL-1α or β will induce an acute phase response in mice (Moldawer et al, 1988) and that the administration of antibodies to the IL-1 receptor will attenuate the acute phase response to turpentine abscess in mice (Gerschenwald et al, 1990) . It is thought that the acute phase response is primarily activated by IL-6 (Castell et al, 1990) but it has been suggested that blockade of IL-1 action will reduce IL-6 production (Yasumoto et al, 1995) . In the present study we failed to identify any simple relationship between serum CRP levels and IL-1β production although IL-1β genotype again seemed to be important with those possessing allele 2 having significantly higher CRP levels than those without.
The administration of pro-inflammatory cytokines, including IL-1, IL-6, interferon-α and TNF, produces features of cachexia in experimental models (Mahony and Tisdale, 1988; Hellerstein et al, 1989; Gelin et al, 1991; Matthys et al, 1991; Strassmann et al, 1992) . These agents all induce an acute phase response and it has been suggested that the need for amino acids to manufacture acute phase reactants in the absence of adequate nutritional intake contributes to breakdown of skeletal muscle and so the weight loss of cachexia (Reeds et al, 1994) . We have previously shown that the presence of an acute phase response is associated with nutritional decline and poor survival in pancreatic cancer (Falconer et al, 1994 (Falconer et al, , 1995 Wigmore et al, 1997) . In this study we have shown that IL-1β genotype is related to survival. The stepwise decrease in median survival between the 1/1, 1/2 and 2/2 genotypes would appear to correspond with the apparent increase in IL-1β production and would therefore be compatible with the hypothesis that a more marked pro-inflammatory state is detrimental to survival in pancreatic cancer, perhaps due to nutritional decline. It has also been suggested that pro-inflammatory cytokines will promote tumour growth in animal models (Gelin et al, 1991) . Blockade of the IL-1 receptor has been shown to reduce liver metastasis in a melanoma model (Vidal-Vanaclocha et al, 1994) perhaps due to an IL-1 induced increase in endothelial receptor expression (Vidal-Vanaclocha et al, 1996) .
The very poor survival of patients with 2/2 genotype is of limited value clinically due to the low prevalence of this genotype, however, the possession of allele 2 was also a significant predictor of survival. This was present in a third of the cancer patients in the present study and almost a half of the population as a whole so it may be a valuable clinical tool for predicting survival. It has been suggested that endoscopic palliation of jaundice rather than surgical biliary bypass is appropriate in those patients with a life expectancy of 6 months or less (van den Bosch et al, 1994; Rosewicz and Weidenmann, 1997) . Existing measures of the inflammatory state are sensitive to surgery, infection and jaundice while IL-1β genotype is not. Using this method to predict 6-month survival had an accuracy of 67% in the current study suggesting that it may be useful in guiding palliative biliary drainage in these patients.
In conclusion, IL-1β genotype is related to IL-1β production and the level of the acute phase protein response and affects survival in patients with advanced pancreatic cancer.
